Target

CD123

Interleukin-3 receptor subunit alpha

Also: IL3RA

21open trials
46trials in total
19publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
CAR-T Immunotherapy Targeting CD19- ALL
1 Jul 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Universal CAR-T Cells Targeting AML
30 Jun 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Retraction notice to "Corrigendum to SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells" [Life Sci. 232 (2019) 116663].
4 Nov 2026· Life sciences· PUBMED
Publication
Retraction notice to "SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells" [Life Sci. 232 (2019) 116663].
2 Nov 2026· Life sciences· PUBMED
Publication
A novel CD123xVδ2 bispecific T cell engager induces potent and tumor selective Vγ9Vδ2-T cell activity against CD123 expressing acute myeloid leukemia and myelodysplastic syndrome.
23 Oct 2026· Clinical immunology (Orlando, Fla.)· PUBMED
Publication
Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells.
16 Oct 2026· Molecular biomedicine· PUBMED
Trial
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
1 Oct 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Functional evaluation of CAR-T anti-CD123 from immune-mediated inflammatory diseases patients for novel pDCs-targeted immunotherapy.
30 Sept 2026· The Journal of allergy and clinical immunology· PUBMED
Trial
Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
23 Sept 2026· PHASE1 · RECRUITING· CTGOV
Trial
Study testing a new experimental cell therapy in adults and children With Relapsed or Refractory Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm
1 Sept 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTIS
Publication
Prognostic impact of CD123 overexpression on the outcome of pediatric acute myeloid leukemia.
21 Aug 2026· Frontiers in oncology· PUBMED
Publication
Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis.
12 Aug 2026· Frontiers in pediatrics· PUBMED
Publication
A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm.
7 Aug 2026· Journal of hematology & oncology· PUBMED
Publication
Targeted efficacy of BCG Hsp70-anti-CD123 immunoconjugate in childhood acute myeloid leukemia.
15 Jun 2026· Pediatric research· PUBMED
Publication
Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax.
11 Jun 2026· Annals of hematology· PUBMED
Publication
Anti-CD123 monoclonal antibodies as therapeutic agents for acute myeloid leukemia: a systematic review.
11 Jun 2026· Expert review of hematology· PUBMED
Trial
4SCAR-T Therapy Post CD19-targeted Immunotherapy
1 Jun 2026· PHASE1_PHASE2 · TERMINATED· CTGOV
Trial
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
14 May 2026· PHASE1 · RECRUITING· CTGOV
Publication
Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signatures.
14 May 2026· Discover oncology· PUBMED
Publication
Context-Dependent Regulation of Microglial Metabolic and Immune States via IL-3/CD123 Signaling: Implications for Glial Crosstalk and Cognitive Impairment.
24 Apr 2026· Molecular neurobiology· PUBMED
Publication
Treatment of acute myeloid leukemia using CD3/CD123 bispecific antibody-engaged γδT cells in a mouse xenograft model.
27 Mar 2026· Tissue & cell· PUBMED
Trial
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
2 Mar 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Aberrant CD25 and Increased CD123 Expression Are Common in Acute Myeloid Leukemia with KMT2A Partial Tandem Duplication and Are Associated with FLT3 Internal Tandem Duplication.
16 Jan 2026· Cancers· PUBMED
Publication
Current status and future potential of CD123-based targeted therapies for acute leukemia.
23 Dec 2025· Expert opinion on biological therapy· PUBMED
Publication
Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities.
21 Nov 2025· Molecular therapy. Oncology· PUBMED
Publication
Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.
18 Nov 2025· British journal of haematology· PUBMED
Trial
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
30 Sept 2025· EARLY_PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
Multiple CAR-T Cell Therapy Targeting AML
1 Aug 2025· PHASE1_PHASE2 · TERMINATED· CTGOV
Trial
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
1 Aug 2025· PHASE1_PHASE2 · TERMINATED· CTGOV

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error